Everything below concerns Pharmacopeial monograph. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-06. Numbers and descriptions here follow the published literature rather than marketing material.
Creatine was first identified in skeletal muscle extracts in the nineteenth century, and its role in phosphagen energy buffering was clarified in the twentieth century. The monohydrate salt became widely studied after methods for inexpensive synthesis and crystallization were developed. Modern research examines its effects on muscle energetics, recovery, and cognitive performance under specific conditions. Findings vary with population, exercise protocol, baseline creatine status, and measurement method. Studies often compare supplementation with placebo during controlled training or testing schedules.
Creatine monohydrate is a hydrated form of creatine, a nitrogen-containing compound involved in cellular energy metabolism. Its molecular formula is C4H9N3O2·H2O, with a molar mass around 149.15 g/mol. The monohydrate is the most common solid form used in research and commercial settings because it crystallizes readily and remains stable under ordinary conditions. The term monohydrate indicates one water molecule per creatine molecule in the crystal lattice. It appears as a white crystalline powder with low odor.
In the body, creatine is synthesized from arginine, glycine, and methionine, mainly in the liver and kidneys, and is also obtained from foods such as meat and fish. About 95% of body creatine is stored in skeletal muscle, where a fraction is phosphorylated to phosphocreatine. Phosphocreatine serves as a rapid reserve of high-energy phosphate for short bursts of ATP regeneration. The monohydrate form supplies creatine after dissolution and absorption, but it is not itself the active phosphorylated species.
Creatine is synthesized endogenously in humans, mainly in the liver, kidney, and pancreas, from the amino acids arginine, glycine, and methionine. Skeletal muscle stores much of the body's creatine, where it participates in the phosphocreatine system that buffers adenosine triphosphate during short, intense contractions. Dietary sources include meat and fish, so omnivorous diets provide additional creatine beyond endogenous production. Supplemental creatine monohydrate supplies the same molecule found in food and tissues, not a distinct drug or hormone. Research interest centers on its role in cellular energy transfer and its effects on muscle and other tissues.
Several creatine forms are sold, including monohydrate, anhydrous, hydrochloride, nitrate, citrate, and blends. Once dissolved, these forms deliver creatine, but they differ in molar mass, solubility, counterions, and water content. Creatine monohydrate has the largest body of published human data among these forms. Questions remain about whether any alternative form offers meaningful advantages in absorption, tolerability, or tissue uptake under practical conditions. The hydrate form's lower creatine content by mass is a compositional fact, not a statement about effectiveness.
Creatine monohydrate is a crystalline compound formed when one molecule of creatine associates with one molecule of water in the solid lattice. Its molecular formula is C4H11N3O3, and its molar mass is about 149.15 grams per mole. The material appears as a white, odorless powder that dissolves sparingly in water at room temperature. The monohydrate designation distinguishes it from anhydrous creatine, which lacks the bound water and has a lower molar mass. This hydrate is the most common commercial form of creatine used in nutritional and research settings.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C4H9N3O2·H2O | Creatine plus one water molecule in the crystal lattice. |
| Molar mass | 149.15 g/mol | Calculated for the monohydrate form. |
| Appearance | White crystalline powder | Typical solid form; particle size can vary by processing. |
| Solubility class | Sparingly soluble in water | Dissolution improves with time, stirring, and temperature. |
| Common synonyms | Creatine hydrate; N-carbamimidoyl-N-methylglycine monohydrate | Names vary by chemical registry and supplier. |
As a supplement, creatine monohydrate is studied for its effects on muscle performance and recovery. The compound is often described as an ergogenic aid, meaning it may support physical work capacity. Research typically compares it with placebo or other forms, such as citrate or nitrate, under controlled conditions. Questions remain about the optimal dose and long-term effects in different populations, and findings are not uniform across all studies. The monohydrate form remains the most extensively tested.
Creatine monohydrate is a crystalline compound formed from creatine and one molecule of water. Its systematic name is N-(aminoiminomethyl)-N-methylglycine monohydrate, and it appears as a white, odorless powder with limited solubility in water. The monohydrate is the most common solid form used in research and commercial products because it is stable under dry conditions. The anhydrous form lacks the water of crystallization and differs slightly in molar mass. Both forms participate in the same biochemical reactions once dissolved.
Regulatory treatment of creatine monohydrate varies by country and intended use. In some jurisdictions it is sold as a dietary supplement, while in others it may be treated as a food ingredient or a pharmaceutical raw material. Pharmacopeial monographs, where available, define identification, assay limits, and impurity thresholds. Manufacturers often follow these monographs or internal specifications to ensure batch-to-batch consistency. Analytical method validation is important because different methods can yield different apparent purity values if sample preparation or detection conditions are not controlled.
Quality control for creatine monohydrate begins with identity confirmation and assay determination. Laboratories commonly use high-performance liquid chromatography with ultraviolet detection, often after derivatization or using a suitable column, to quantify creatine. Karl Fischer titration measures water content, which helps verify the monohydrate stoichiometry. Additional tests screen for heavy metals, residual solvents, and microbial contamination depending on the intended use. These tests establish composition and purity rather than biological effect.
Commercial creatine products appear in several forms, including monohydrate, hydrochloride, citrate, nitrate, and ethyl ester. Creatine monohydrate is the most studied form and serves as a reference material in comparative research. Different forms vary in solubility, pH, and water content, but they share creatine as the active moiety after dissolution. Claims that one form is uniformly superior remain debated, and study designs often differ in population, exercise protocol, and outcome measures. Purity and hydration state are central to interpreting product labels.
Creatine monohydrate is the hydrated form of creatine, a nitrogen-containing organic acid involved in cellular energy transfer. Its molecular formula is C4H11N3O3, and it consists of creatine plus one water molecule in the crystal lattice. The anhydrous base, creatine, has the formula C4H9N3O2. The compound appears as a white, odorless, crystalline powder and is classified as a guanidine derivative. It is distinct from creatinine, a breakdown product measured in clinical chemistry.
In animals, creatine is synthesized mainly in liver, kidney, and pancreas from arginine, glycine, and methionine. The first committed step transfers a guanidino group from arginine to glycine, forming guanidinoacetate. Subsequent methylation by S-adenosylmethionine yields creatine. Dietary sources include meat and fish; endogenous synthesis supplies part of the body pool. Most creatine is stored in skeletal muscle, where it is converted to phosphocreatine and participates in rapid regeneration of adenosine triphosphate during short, intense activity.
In the human body, creatine is synthesized mainly in the liver and kidneys from the amino acids glycine, arginine, and methionine. Dietary sources include meat, fish, and other animal tissues, which supply preformed creatine. Because plant foods contain little or no creatine, dietary intake varies widely among populations. The compound is stored largely in skeletal muscle, where it is converted to phosphocreatine and used to regenerate adenosine triphosphate during short bursts of activity.
Creatine monohydrate is one of several solid forms of creatine described in the literature. Other forms include anhydrous creatine, creatine hydrochloride, and creatine ethyl ester, each with different solubility and stability characteristics. The monohydrate is distinct from creatinine, a spontaneous breakdown compound that forms when creatine loses water and cyclizes. Commercial descriptions sometimes use synonyms such as methylguanidoacetic acid or N-(aminoiminomethyl)-N-methylglycine, which refer to the same base molecule. These names appear in chemical databases and product labels.
Creatine monohydrate is a crystalline compound formed when one molecule of creatine binds with one molecule of water. Creatine itself is a nitrogen-containing organic acid involved in cellular energy transfer, particularly in muscle and nerve tissue. The monohydrate form is the most common solid form used in research and commercial products because it is relatively stable and easy to handle. Its molecular formula is C4H9N3O2·H2O, and its molar mass is about 149.15 grams per mole.
=== Intellectual origins === While Nick Land is seen as the intellectual originator of contemporary accelerationism in general, the precise origins of effective accelerationism remain unclear. The earliest known reference to the movement can be traced back to a May 2022 newsletter published by four pseudonymous authors known by their X (formerly Twitter) usernames @BasedBeffJezos, @bayeslord, @zestular and @creatine_cycle. According to Émile Torres, effective accelerationism is an extension of the TESCREAL movement, being etymologically derived from effective altruism and heavily rooted in the older Silicon Valley subcultures of transhumanism and extropianism (which similarly emphasized the value of progress and resisted efforts to restrain the development of technology), alongside elements of singularitarianism, cosmism, and longtermism. It is also often considered to have emerged at least in part from the work of the Cybernetic Culture Research Unit (of which Nick Land was a leading member, alongside writers such as Mark Fisher and Sadie Plant).
== Prognosis == Regardless of cause, UIP is relentlessly progressive, usually leading to respiratory failure and death without a lung transplant. Some patients do well for a prolonged period of time, but then deteriorate rapidly because of a superimposed acute illness (so-called "accelerated UIP"). The outlook for long-term survival is poor. In most studies, the median survival is 3 to 4 years. Patients with UIP in the setting of rheumatoid arthritis have a slightly better prognosis than UIP without a known cause (IPF).
Breast hypertrophy is a rare medical condition of the breast connective tissues in which the breasts become excessively large. The condition is often divided based on the severity into two types, macromastia and gigantomastia. Hypertrophy of the breast tissues may be caused by increased histologic sensitivity to certain hormones such as female sex hormones, prolactin, and growth factors. Breast hypertrophy is a benign progressive enlargement, which can occur in both breasts (bilateral) or only in one breast (unilateral). It was first scientifically described in 1648.
=== Pharmacodynamics === Sarcosine acts as a competitive inhibitor of GlyT1, a glycine transporter that is predominantly expressed on glial cells and is responsible for the reuptake of glycine from the synaptic cleft in the central nervous system. By blocking GlyT1, sarcosine elevates the extracellular concentration of glycine in the vicinity of NMDA receptors, thereby augmenting NMDA receptor-mediated neurotransmission. In addition to its indirect enhancement of NMDA receptor function via GlyT1 blockade, sarcosine directly acts as a co-agonist at the glycine binding site (also termed the GluN1 site) of the NMDA receptor. It increases NMDA-mediated currents in a dose-dependent manner. Sarcosine differs from glycine as a co-agonist in that it produces markedly less NMDA receptor desensitization at subsaturating concentrations. At equivalent receptor occupancy (EC20 to EC50), sarcosine significantly slowed the rate of glycine-dependent desensitisation compared with glycine itself, whereas the rate of glycine-independent desensitisation was similar for both ligands. At concentrations higher than those required for GlyT1 inhibition or NMDA receptor co-agonism, sarcosine additionally activates strychnine-sensitive glycine receptors (GlyRs). It evokes a chloride current that is dose-dependent, inhibited by strychnine, and shows a lack of additivity with glycine. Sarcosine is less potent and efficacious than glycine at GlyRs, potentially due to steric constraints imposed by the N-methyl group within the glycine binding site on the receptor.
Sources: en.wikipedia.org
Cell growth and proliferation are affected by G6PD. Pharmacologically ablating G6PD has been shown to overcome cross-tolerance of breast cancer cells to anthracyclines. G6PD inhibitors are under investigation to treat cancers and other conditions. In vitro cell proliferation assay indicates that G6PD inhibitors, DHEA (dehydroepiandrosterone) and ANAD (6-aminonicotinamide), effectively decrease the growth of AML cell lines. G6PD is hypomethylated at K403 in acute myeloid leukemia, SIRT2 activates G6PD to enhance NADPH production and promote leukemia cell proliferation.
The ribosomal RNA core is represented as a grey tube, expansion segments are shown in red. Universally conserved proteins are shown in blue. These proteins have homologs in eukaryotes, archaea and bacteria. Proteins Shared only between eukaryotes and archaea are shown in orange, and proteins specific to eukaryotes are shown in red.
=== RNA editing and the genome === Octopuses, like other coleoid cephalopods but unlike more basal cephalopods or other molluscs, are capable of greater RNA editing, changing the nucleic acid sequence of the primary transcript of RNA molecules, than any other organisms. Much editing is done in the nervous system, particularly for excitability and neuronal morphology. Coleoids rely mostly on ADAR enzymes for RNA editing, which requires large, double-stranded RNA structures. The many editing sites are conserved in the coleoid genome and the mutation rates for the sites are hampered. Hence, greater transcriptome plasticity has come at the cost of slower genome evolution. The genome of octopuses has also gone through several chromosomal fusions and rearrangements, unlike that of their closest relative the vampire squid, whose chromosomal structure is more basal and squid-like. The octopus genome is unremarkably bilaterian except for large developments of two gene families: protocadherins, which regulate the development of neurons; and the C2H2 zinc-finger transcription factors. Many novel genes in both cephalopods generally and octopus specifically manifest in the animals' skin, suckers, and nervous system.
Benzydamine (also known as Tantum Verde and branded in some countries as Maxtra Gargle, Difflam and Septabene), available as the hydrochloride salt, is a locally acting nonsteroidal anti-inflammatory drug (NSAID) with local anaesthetic and analgesic properties for pain relief and anti-inflammatory treatment of inflammatory conditions of the mouth and throat. It falls under class of chemicals known as indazoles.
In a poor, shallow latch, the infant may latch close to, or at, the nipple, which can cause the mother pain. While the infant is at the breast, the first indicators of a shallow latch are having the areola be largely visible outside the infant's mouth and a narrow infant mouth angle. Additional signs result from poor positioning when the infant comes toward the breast to latch. If the infant leads with their brow or forehead, they are likely to flex their neck; this latching mechanism causes the nipple to point down and then hit the hard palate during sucking. From an external view, this manifests as the nose and forehead being close to the breast and the chin far from the breast. This neck flexion also obstructs the normal swallowing mechanism, preventing the infant from drinking efficiently. In addition to not being able to swallow properly, this shallow latch prevents the infant from adequately compressing the glandular tissue behind the nipple and stimulating milk flow; thus, they may begin to apply more suction, which manifests externally as cheek dimpling, or sucking their cheeks in.
Sources: en.wikipedia.org
Creatine is the base compound, while creatine monohydrate is a solid crystalline form that contains one water molecule per creatine molecule. Once dissolved, the monohydrate dissociates and releases creatine, which can participate in cellular energy metabolism. The monohydrate is the form most commonly used in research and commercial products.
Meat and fish contain creatine, and the human body also synthesizes it from amino acids. The monohydrate form is not a natural food ingredient as such; it is a manufactured crystalline solid that provides creatine after ingestion. Food sources contribute to total body creatine stores alongside endogenous synthesis.
It means the crystal lattice includes one molecule of water for each molecule of creatine. This water is part of the solid's ordered structure, not bulk moisture. The hydrate form influences properties such as solubility, density, and shelf stability.
It is the hydrated crystalline form of creatine, containing one bound water molecule per creatine unit. The compound is commonly used as a nutritional ingredient and as a research material.